SCHEMBL2648673

SCHEMBL2648673

CC(C)c1nc(C(C)C)c(CN2CCC(N3CCCCC3)CC2)c(-c2ccc(F)cc2)c1CO

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCGR P47871 15/20 0.56
TRPV4 Q9HBA0 4/20 0.40
TACR2 P21452 2/20 0.40
TACR3 P29371 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649565 0.90 GCGR (0.65) GCGR
SCHEMBL2654771 0.88 GCGR (0.67) GCGR
SCHEMBL2649966 0.84 GCGR (0.61) GCGRTRPV4TACR2TACR3
SCHEMBL2662957 0.83 GCGR (0.57) GCGR
SCHEMBL2648171 0.81 GCGR (0.62) GCGR
SCHEMBL2647836 0.78 GCGR (0.58) GCGR
SCHEMBL8949822 0.78 GCGR (0.88) GCGR
SCHEMBL8949900 0.74 GCGR (0.62) GCGR
SCHEMBL2647465 0.74 GCGR (0.61) GCGR
SCHEMBL9072604 0.73 GCGR (0.52) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
WO-1998004528-A2 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS BAYER CORPORATION (US) 1998-02-05 WO disclosed